MARKET

ACIU

ACIU

AC Immune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.99
+0.12
+1.75%
Closed 17:38 09/17 EDT
OPEN
6.87
PREV CLOSE
6.87
HIGH
7.02
LOW
6.80
VOLUME
312.74K
TURNOVER
--
52 WEEK HIGH
12.61
52 WEEK LOW
4.420
MARKET CAP
507.84M
P/E (TTM)
-6.2865
1D
5D
1M
3M
1Y
5Y
Alzheimer's Drug for Roche Partner AC Immune Shows Promise
GuruFocus News · 3d ago
AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the Year
AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced its Co-Founder and CEO Andrea Pfeifer has been awarded by the Swiss Economic Forum (SEF) with ...
GlobeNewswire · 09/03 11:52
AC Immune Files For U.S. Patent Titled 'Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates'
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=6704&p=135&f=G&l=50&d=PG01&S1=20210902.PD.&OS=PD/20210902&RS=PD/20210902
Benzinga · 09/02 13:45
AC Immune to Participate in Upcoming Virtual Investor Conferences in September
LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in the ...
GlobeNewswire · 09/02 11:00
AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study
AC Immune's (ACIU) candidate for mild-to-moderate AD meets one of the two co-primary endpoints. Resultantly, the stock price rises 16%
Zacks · 09/01 15:30
Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More
Regulatory and pipeline updates from Regeneron (REGN) and Incyte (INCY), among others, have been in focus in the biotech industry over the past week.
Zacks · 09/01 14:44
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 11:32
Mid-Afternoon Market Update: Spok Holdings Surges On Takeover Offer; Sequential Brands Shares Slide
Toward the end of trading Tuesday, the Dow traded down 0.09% to 35,366.93 while the NASDAQ fell 0.02% to 15,263.43. The S&P also fell, dropping 0.11% to 4,523.94.
Benzinga · 08/31 18:26
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACIU. Analyze the recent business situations of AC Immune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACIU stock price target is 15.01 with a high estimate of 16.82 and a low estimate of 12.37.
EPS
Institutional Holdings
Institutions: 75
Institutional Holdings: 18.66M
% Owned: 25.69%
Shares Outstanding: 72.65M
TypeInstitutionsShares
Increased
16
1.69M
New
16
3.09M
Decreased
18
1.93M
Sold Out
10
2.86M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Douglas Williams
Chief Executive Officer/Co-Founder/Director/IR Contact Officer
Andrea Pfeifer
Non-Executive Vice Chairman/Independent Director
Martin Velasco
Chief Financial Officer
Joerg Hornstein
Chief Operating Officer/Chief Technology Officer
Piergiorgio Donati
Chief Administrative Officer
Jean-Fabien Monin
Chief Scientific Officer
Marie Kosco-Vilbois
Other
Johannes Streffer
Non-Executive Independent Director
Peter Bollmann
Non-Executive Independent Director
Thomas Graney
Non-Executive Independent Director
Carl June
Non-Executive Independent Director
Werner Lanthaler
Non-Executive Independent Director
Roy Twyman
No Data
About ACIU
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Webull offers kinds of AC Immune SA stock information, including NASDAQ:ACIU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACIU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACIU stock methods without spending real money on the virtual paper trading platform.